Your session is about to expire
← Back to Search
MIND at Home Program for Dementia
N/A
Waitlist Available
Led By Elizabeth L Ciemins, PhD
Research Sponsored by American Medical Group Association
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up data will be collected monthly for the 3 months prior to enrollment, the 3 months during enrollment, and one month post enrollment.
Awards & highlights
Study Summary
This trialseeks to test a program that will help people living with dementia stay in their homes and be better cared for by primary care doctors at lower costs.
Who is the study for?
This trial is for adults over 18 with dementia who live in the community and have a reliable care partner. They must be diagnosed with dementia as defined by CMS, be receiving primary care at selected sites, and commit to participating in all study activities for 3 months.Check my eligibility
What is being tested?
The MIND at Home program is being tested to see if it can improve care for people living with dementia (PLWD) by integrating Memory Care Coordinators into primary care. It includes home visits, assessments, personalized care plans, and ongoing support.See study design
What are the potential side effects?
Since this trial involves a non-medical intervention focusing on coordinated care rather than medication or medical procedures, traditional side effects are not applicable. However, there may be changes in healthcare utilization patterns.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ data will be collected monthly for the 3 months prior to enrollment, the 3 months during enrollment, and one month post enrollment.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~data will be collected monthly for the 3 months prior to enrollment, the 3 months during enrollment, and one month post enrollment.
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in Number of Hospital Transfers Pre/Post Intervention
Secondary outcome measures
Change in Number of Medications Pre/Post Intervention
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Group I: Intervention Arm: PLWD CPsExperimental Treatment1 Intervention
150 Care Partners (CPs) of the 150 community-residing PC patients with an ADRD diagnosis will be enrolled and receive MIND coordination services for 3 months to test program implementation feasibility in PC practice settings.
Group II: Intervention Arm: PLWDExperimental Treatment1 Intervention
150 community-residing PC patients with an ADRD diagnosis will be enrolled and receive MIND coordination services for 3 months to test program implementation feasibility in PC practice settings.
Group III: Data Validation ArmActive Control1 Intervention
An additional 100 PLWD will serve as a data validation arm to demonstrate the feasibility of collecting and validating data from large health systems.
Find a Location
Who is running the clinical trial?
CommonSpirit HealthUNKNOWN
Johns Hopkins UniversityOTHER
2,259 Previous Clinical Trials
14,820,253 Total Patients Enrolled
31 Trials studying Dementia
82,402 Patients Enrolled for Dementia
Brown UniversityOTHER
456 Previous Clinical Trials
562,681 Total Patients Enrolled
19 Trials studying Dementia
207,919 Patients Enrolled for Dementia
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am willing to commit to a 3-month study, including home visits.I have a care partner who can communicate with the Memory Care Coordinator.I am an adult over 18 living in a community setting.
Research Study Groups:
This trial has the following groups:- Group 1: Intervention Arm: PLWD
- Group 2: Intervention Arm: PLWD CPs
- Group 3: Data Validation Arm
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any open opportunities to join this investigation?
"Clinicaltrials.gov shows that this experiment is actively recruiting appropriate individuals. The trial was initially advertised on July 18th 2022 and altered for the last time in November 17th 2022."
Answered by AI
How many individuals can potentially join this experiment?
"Affirmative. Based on clinicaltrials.gov, this research initiative is open to enrolment and began recruiting participants on July 18th 2022. It was most recently updated the 17th of November in the same year; 400 patients are required from a sole site for completion of the trial."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger